Developments in drugs for ovarian stimulation

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 17, Issue 2, 2003, Pages 231-247

  Ludwig, M ^a   Westergaard, L G ^b   Diedrich, K ^a   Andersen, C Yding ^c  

^a University Clinic   (Germany)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Mental Health Services CPH   (Denmark)

Author keywords

Cetrorelix; Ganirelix; GnRH agonists; GnRH antagonist; hMG; Recombinant FSH; Recombinant hCG; Recombinant LH

Indexed keywords

BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN DERIVATIVE; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE; UROFOLLITROPIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; AMENORRHEA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DIARRHEA; DOSE RESPONSE; DOWN REGULATION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG POTENTIATION; DRUG PURIFICATION; DRUG SAFETY; DRUG SYNTHESIS; DYSPNEA; FERTILIZATION IN VITRO; HORMONAL REGULATION; HORMONE ACTION; HUMAN; INCIDENCE; INFERTILITY; INHIBITION KINETICS; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; META ANALYSIS; NAUSEA; NONHUMAN; OOCYTE DEVELOPMENT; OOCYTE MATURATION; OVARY CYST; OVARY FOLLICLE DEVELOPMENT; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PATIENT CARE; PHARMACODYNAMICS; PHARMACOLOGICAL STIMULATION; PREGNANCY RATE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPONTANEOUS ABORTION; VOMITING;

EID: 0037765943     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6934(02)00168-2     Document Type: Review

References (52)

1. Gemzell C. Induction of ovulation with human gonadotropins. Recent Progress of Hormonal Research 1965; 21: 179-204.
2. Lunenfeld B, Sulimovici S, Rabau E & Eshkol A. L'induction de l'ovulation dans les amenorrhees hypophysaires par un traitement combine de gonadotrophins urinaires menopausiques et de gonadotrophins chorioniques. Comptes Rendus de la Societe Francaise de Gynecologie 1962; 5: 1-5.
3. Stockman PGW, Leeuw R, Van Den Wijngaard HAGW et al. Human chorionic gonadotrophin in commercial menopausal gonadotropin. Fertility and Sterility 1993; 60: 175-178.
4. Giudice E, Crisci C, Eshkol A & Papoian R. Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: Characterization of non-gonadotrophin proteins. Human Reproduction 1994; 9: 2291-2299.
5. Eshkol A & Lunenfeld B. Purification and separation of follicle stimulating hormone (FSH) and luteinizing hormone (LH) from human menopausal gonadotrophin (hMG). Part III. Acta Endocrinologica 1967; 54: 919-931.
6. LeCotonnec J-Y, Porchet HC, Beltrami VC & Howles CM. Comparative pharmacokinetics of urinary follicle stimulating hormone preparations in healthy female and male volunteers. Human Reproduction 1993; 8: 1604-1611.
7. Chappel S, Kelton C & Nugent N. Expression of human gonadotropins by recombinant DNA methods. In Genazzi AR & Petraglia F (eds) Proceedings of the 3rd World Congress on Gynecological Endocrinology, pp 179-184, Carnfort, UK: Parthenon Publishing Group, 1992.
8. Dicsfalusy E & Harlin J. Clinical-pharmacological studies on human menopausal gonadotrophin. Human Reproduction 1988; 3: 21-27.
9. Baird DT & Howles CM. Induction of ovulation with gonadotrophins: hMG versus purified FSH. In Filicori M & Flagmini C (eds) Ovulation Induction: Basic Science and Clinical Advances, pp 135-143, Amsterdam: Elsevier Science BV, 1994.
10. Filicori M, Cognigni GE, Taraborelli S et al. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. Journal of Clinical Endocrinology and Metabolism 1999; 84: 2659-2663.
11. Howles CM. Role of LH and FSH in ovarian function. Molecular Cellular Endocrinology 2000; 161: 25-30.
12. Fleming R, Rehka P, Deshpande N et al. Suppression of LH during ovarian stimulation: Effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Human Reproduction 2000; 15: 1440-1445.
13. Westergaard LG, Laursen SB & Yding Andersen C. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Human Reproduction 2000; 15: 1003-1008.
14. Fleming R & Coutts JTR. Induction of multiple follicular growth in normally menstruating women after gonadotrophin-releasing hormone agonist suppression. Fertility and Sterility 1986; 45: 226-230.
15. Hughes EG, Fedorkow DM, Daya S et al. The routine use of gonadotrophin-releasing hormone agonist prior to in vitro fertilization and gamete intrafallopian transfer: A meta-analysis of randomized controlled studies. Fertility and Sterility 1992; 58: 888-896.
16. Chappel SC & Howles C. Re-evaluation of the roles of luteinizing hormone and follicle stimulating hormone in the ovulatory process. Human Reproduction 1991; 6: 1206-1212.
17. Stanger JD & Yovich JL. Reduced in vitro fertilisation of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. British Journal of Obstetrics and Gynaecology 1985; 92: 385-393.
18. Howles CM, MacNamee MC, Edwards RG et al. Effect of high tonic levels of luteinizing hormone on outcome of in vitro fertilisation. Lancet 1986; ii: 521-522.
19. Regan L, Owen EJ & Jacobs HS. Hypersecretion of luteinizing hormone, infertility and miscarriage. Lancet 1990; 336: 1141-1144.
20. Daya S, Gunby J, Hughes EG et al. Randomized controlled trial of follicle stimulating hormone versus human menopausal gonadotrophin in in-vitro fertilization. Human Reproduction 1995; 10: 1392-1396.
21. Agrawal R, Holmes J & Jacobs HS. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilisation cycles: A meta-analysis. Fertility and Sterility 2000; 73: 338-343.
22. Out HJ, Mannaerts BMJL, Driessen SGAJ & Coelingh Bennink HJT. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle-stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Human Reproduction 1995; 10: 2534-2540.
23. Fleming R, Lloyd F, Herbert M et al. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Human Reproduction 1998; 13: 1788-1792.
24. Fanchin R, Schoenauer LM, Jahjoub S et al. Residual LH concentration after GnRH agonist administration influences ovarian response to recombinant FSH, embryo quality, and IVF-embryo transfer outcome. Human Reproduction 2001; 16: 14-15. abstract book.
25. Balasch J, Vidal E, Penarrubia J et al. Suppression of LH during ovarian stimulation: Analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. Human Reproduction 2001; 16: 1636-1643.
26. Westergaard LG, Erb K, Laursen S et al. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotrophic women down-regulated with a gonadotrophin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic injection: A prospective randomized study. Fertility and Sterility 2001; 76: 543-549.
27. Kelly EE & Nebiolo L. Recombinant FSH therapy alone (Gonal-F) versus combination therapy (Gonal-F + Lhadi, R-hLH) in patients down-regulated with low dose luteal GnRH agonist protocol. Preliminary results. 11th World Congress on In Vitro Fertilization and Human Reproductive Genetics 1999. Abstract S-003. Sydney.
28. Ng EHY, Lau EYL, Yeung WSB & Ho PC. HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: A prospective randomized trial. Human Reproduction 2001; 16: 319-325.
29. Gordon UD, Harrison RF, Fawzy M et al. A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome. Fertility and Sterility 2001; 75: 324-331.
30. Strehler E, Markus A, Imam E et al. Impact of recombinant follicle-stimulating hormone and human menopausal gonadotropins on in vitro fertilization outcome. Fertility and Sterility 2001; 75: 332-336.
31. Tesarik J & Mendoza C. Non-genomic effects of 17-estradiol on maturing human oocytes: Relationship to oocyte developmental potential. Journal of Clinical Endocrinology and Metabolism 1995; 80: 1438-1443.
32. The European Recombinant LH Study Group. Recombinant human luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: Results of a multicenter double-blind study. Journal of Clinical Endocrinology and Metabolism 2001; 86: 2607-2618.
33. Duffy DM, Hutchinson JS, Stewart DR & Stouffer RL. Stimulation of primate luteal function by recombinant human chorionic gonadotropin and modulation of steroid, but not relaxin, production by an inhibitor of 3 beta-hydroxysteroid dehydrogenase during stimulated early pregnancy. Journal of Clinical Endocrinology and Metabolism 1996; 81: 2307-2313.
34. The European Recombinant Human Chorionic Gonadotrophin Study Group. Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment - rhCG versus urinary hCG. Human Reproduction 2000; 15: 1446-1451.
35. Chang P, Kenley S, Burns T et al. Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: Results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization-embryo transfer. Fertility and Sterility 2001; 76: 67-74.
36. Driscoll GL, Tyler JP, Hangan JT et al. A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary hCG for inducting oocyte maturation and follicular luteinization in ovarian stimulation. Human Reproduction 2000; 15: 1305-1310.
37. Zelinski-Wooten MB, Hutchison JS, Trinchard-Lugan I et al. Initiation of periovulatory events in gonadotrophin-stimulated macaques with varying doses of recombinant human chorionic gonadotrophin. Human Reproduction 1997; 12: 1877-1885.
38. Albano C, Felberbaum RE, Smitz J et al. Controlled ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the LHRH-antagonist Cetrorelix (Cetrotide) and the LHRH-agonist Buserelin. Human Reproduction 2000; 15: 526-531.
39. Olivennes F, Belaisch-Allart J, Emperaire JC et al. A prospective randomized controlled study in IVF-ET with a single dose of a LH-RH antagonist (Cetrorelix) or a depot formula of a LH-RH agonist (Triptorelin). Fertility and Sterility 2000; 73: 314-320.
40. Roulier R, Chabert-Orsini V, Sitri MC & Barry B. Utilisation des antagonistes de la LHRH (Cetrotide® 3 mg) en pratique courante dans une population non électionnée: Étude prospective, randomisée, comparative versus agonistes retard de la GnRH. Federation Française d'Etudes de la Reproduction, Lyon, France: Palais des Congrés, 2001. 5th-7th September.
41. The North American Ganirelix Study Group, Fluker M, Grifo J et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility 2001; 75: 38-45.
42. The European and Middle East Orgalutran® Study Group, Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 2001; 16: 644-651.
43. European Orgalutran Study Group, Mannaerts BMJL & Borm G. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial. Human Reproduction 2000; 15: 1490-1498.
44. Albano C, Felberbaum RE, Smitz J et al. Controlled ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the LHRH-antagonist Cetrorelix (Cetrotide) and the LHRH-agonist Buserelin. Human Reproduction 2000; 15: 526-531.
45. Felberbaum RE, Albano C, Ludwig M et al. Controlled ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the LHRH-antagonist Cetrorelix (Cetrotide®) according to the multiple dose protocol - Results of a prospective non controlled phase III study. Human Reproduction 2000; 15: 1015-1020.
46. Olivennes F, Fanchin R, Bouchard P et al. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: A pilot study. Human Reproduction 1995; 10: 1382-1386.
47. Olivennes F, Fanchin R, Bouchard Ph et al. The single or dual administration of the GnRH antagonist cetrorelix prevents premature LH surges in an IVF-ET program. Fertility and Sterility 1994; 62: 468-476.
48. Olivennes F, Alvarez S, Bouchard P et al. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: A dose finding study of 3 versus 2 mg. Human Reproduction 1998; 13: 2411-2414.
49. Ludwig M, Felberbaum RE, Devroey P et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics 2000; 264: 29-32.
50. Ludwig M, Katalinic A & Diedrich K. Use of GnRH antagonists in ovarian stimulation for ART compared to the long protocol: A meta-analysis. Archives of Gynecology and Obstetrics 2001; 265: 175-182.
51. Felberbaum R, Reissmann T, Küpker W et al. Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist cetrorelix at different dosages. Journal of Assisted Reproduction and Genetics 1996; 13: 216-222.
52. Westergaard LG, Wiberg N, Andersen CY et al. Circulating concentrations of placenta protein 14 during the natural menstrual cycle in women significantly reflect endometrial receptivity to implantation and pregnancy during successive assisted reproduction cycles. Human Reproduction 1998; 13: 2612-2619.